Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (March 2019)
21 slides from Genetic Signatures's investor presentation, March 2019
Slide 1: Investor Presentation
**DRAFT** Investor Presentation March 2019
Slide 2: Disclaimer
Disclaimer This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange
Slide 3: Contents
Contents • Corporate summary 1 • Product overview 2 • Financial and share price growth 3 • Commercialisation strategy 4
Slide 4: Corporate summary
Corporate summary Revenue stage healthcare company listed on the ASX Share price (A$) Volume (m) Genetic Signatures Limited (ASX: GSS) 1.60 0.8 A specialist molecular diagnostics company 1.20 0.6 Focused on becoming a global leader in the supply of molecular diagnostic solutions 0.80 0.4 Developing
Slide 5: GSS snapshot
GSS snapshot Genetic Signatures is commercialising its 3base™ technology, targeting large international markets Genetic Signatures’ 3base™ technology Genetic Signatures EasyScreen™ Portfolio • World-first, proprietary platform technology significantly simplifies genetic detection of microbial organisms
Slide 6: The science behind 3base™ technology
The science behind 3base™ technology 3base™ technology reduces complexity in genetic testing, allowing detection of more pathogens. Extra results, higher accuracy, lower cost 3base™ technology 3base™ technology in the detection process 1 3baseTM platform technology Regular cell Lysis and converts or
Slide 7: The EasyScreen™ competitive advantage
The EasyScreen™ competitive advantage EasyScreen™ offers faster and more effective detection of infectious disease; optimised for high throughput labs High High Rapid time Common Platform throughput specificity to result workflow agnostic Ability to test Superior accuracy Provides optimised Four pro
Slide 8: Powerful evidence of efficacy from clinical trials
Powerful evidence of efficacy from clinical trials Comparative studies confirm superior performance of Genetic Signatures’ technology Clinical trials demonstrate efficacy St Vincent’s Hospital Evaluation Study results Conventional Evaluation study conducted at Pathogen Methods* EasyScreen™ St. Vince
Slide 9: Continued revenue growth in 2Q FY19
Continued revenue growth in 2Q FY19 GSS continues to consistently deliver strong quarter-on-quarter revenue growth over the previous 4 financial years Quarterly revenue (A$k) Key Highlights +83% 1,236 • Existing domestic customers on pcp executing repeat orders and 1,013 purchasing new products with
Slide 10: Financial performance
Financial performance Half year ended Half year ended A$000 31-Dec-18 31-Dec-17 Income includes R&D tax concession (A$1.1m in 1H FY2019) and interest Total sales and other income 3,456 2,458 received (A$0.1m in 1H FY2019) Cost of materials used (789) (521) Employee benefits expense (2,398) (1,857)
Slide 11: Financial performance - cash
Financial performance - cash Half year ended Half year ended A$000 31-Dec-18 31-Dec-17 Receipts from customers 2,302 1,437 Payments to suppliers & employees (4,872) (4,313) Increase in receipts from customers in Interest received 92 146 line with revenue increases R&D tax concession received 2,561
Slide 12: Share price performance
Share price performance Genetic Signatures has made significant operational progress which has been recognised by positive share price perfomance in the last 12 months Share price performance (A$) 1.60 +288% March 2018: Repeat international May 2018: First sales in the August 2018: Major contract wi
Slide 13: Infectious disease – a growing global concern
Infectious disease – a growing global concern Rapid and comprehensive detection of pathogens is an important strategy in reducing the spread of infectious disease. Genetic Signatures’ EasyScreenTM Detection kits identify a larger number of pathogen targets in a shorter time frame than conventional m
Slide 14: Executing a global strategy for commercialisation
Executing a global strategy for commercialisation GSS remains focused on growth in both international and domestic markets 2 Europe: Focused on increasing customer acquisitions with expanding product suite Sales force in place and trials underway 9 Multiple distributors appointed 9 CE-IVD approvals
Slide 15: Board of Directors have a track record of success
Board of Directors have a track record of success Tony Radford Non executive Director • Significant sales experience • Co-Founder and CEO of Cellestis until acquired by Qiagen for c.A$400m • Proven track record of executing a sales strategy into Europe Phillip Isaacs Non executive director Michael A
Slide 16: GSS’ 3base technology is already available in the US
GSS’ 3baseTM technology is already available in the US GSS is achieving increasing traction with ASR approach and early revenue out of the US highlights the commercial potential of 3baseTM technology What is an Analyte Specific Reagent (ASR)? Estimated MDx market size (2017, US$)4 • Components or ‘
Slide 17: Major Australian contract and product launch
Major Australian contract and product launch New customer and product launch created immediate boost to the revenue base 1 Step change in revenue following product Second generation EasyScreen™ launch and new major contract Respiratory Pathogen Detection Kit - • Sales contract signed with a large Au
Slide 18: Driving awareness at key global conferences
Driving awareness at key global conferences Medical and industry conferences are an important means to drive positive exposure of EasyScreenTM and the benefits of 3baseᵀᴹ technology AMP - San Antonio Sheffield Microbe - UK Nov-2018 Oct-2018 Exhibited at the Association for Exhibited the benefits of
Slide 19: Promising clinical trial results
Promising clinical trial results The National CPE Reference Laboratory in Ireland presented successful results from the trial of the EasyScreenTM ESBL & CPO Detection Kit Successful EasyScreenTM ESBL & CPO trial results • The trial was undertaken by Ireland’s National CPO Reference Laboratory • Tria
Slide 20: Multiple upcoming value catalysts
Multiple upcoming value catalysts Objectives Upcoming activities In addition to key upcoming 2019 milestones, GSS will continue to focus on a range of activities delivering value in the near term. Notable activities include: Domestic Europe US 9 Securing new customer TGA approval and CE-IVD registra
Slide 21: Contact us
Contact us Dr John Melki Peter Manley Genetic Signatures Genetic Signatures Chief Executive Officer Chief Financial Officer P: +61 (0)2 9870 7580 P: +61 (0)2 9870 7580 E: john@geneticsignatures.com E: peter.manley@geneticsignatures.com Visit us www.geneticsignatures.com Follow us on social media
Genetic Signatures — Investor Presentation (March 2019) on 6ix